Cohance Lifesciences Ltd (NSE: COHANCE) and Syngene International Ltd. (NSE: SYNGENE) are both listed in the Pharmaceutical CDMO and CRO Services industry. Cohance Lifesciences has a market capitalisation of ₹17,104 Cr and Syngene International ₹16,439 Cr, as of 9 Nov 2026. Their P/E ratios are 95.5 and 52.5 respectively. Return on equity is 5.11% for Cohance Lifesciences and 6.62% for Syngene International. Over one year, Cohance Lifesciences's share price is down 40.3% and Syngene International's is down 33.7%.
| Metric | Cohance Lifesciences | Syngene International |
|---|---|---|
| NSE Symbol | COHANCE | SYNGENE |
| BSE Code | 543064 | 539268 |
| Share Price | ₹443.50 | ₹436.00 |
| Market Cap | ₹17,104 Cr | ₹16,439 Cr |
| P/E Ratio | 95.5 | 52.5 |
| Return on Equity | 5.11% | 6.62% |
| Return on Assets | 2.69% | 4.78% |
| Dividend Yield | 0.00% | 0.30% |
| Beta (1Y) | 0.37 | -0.08 |
| 1-Year Price Change | -40.3% | -33.7% |
| 3-Month Price Change | -0.8% | +8.3% |
| 52-Week Range | ₹266.70 – ₹715.00 | ₹344.45 – ₹678.95 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹477 Cr | ₹833 Cr |
| Quarterly Net Profit | ₹2 Cr | ₹32 Cr |
| Net Margin | 0.5% | 3.9% |
| EPS (Basic, Quarter) | ₹0.40 | ₹0.80 |
| Results Basis | consolidated | consolidated |
| Headquarters | Hyderabad, Telangana | Bengaluru, Karnataka |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and …
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, i…
Cohance Lifesciences has a market capitalisation of ₹17,104 Cr, against ₹16,439 Cr for Syngene International as of 9 Nov 2026, so the two are about the same size by market cap.
Cohance Lifesciences has a P/E of 95.5 and Syngene International a P/E of 52.5 as of 9 Nov 2026.
Cohance Lifesciences has a return on equity of 5.11% and Syngene International 6.62%.
Cohance Lifesciences's share price is down 40.3% over one year and Syngene International's is down 33.7%.
Cohance Lifesciences reported revenue of ₹477 Cr and net profit of ₹2 Cr for Q2 FY27. Syngene International reported revenue of ₹833 Cr and net profit of ₹32 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.